For investors in Adamis Pharmaceuticals (ADMP), the wait is finally over. On Thursday, Adamis obtained approval for its low-dose Epinephrine medication, Symjepi. The company previously had approval for the 0.30mg version of Symjepi, and the FDA approval of Symjepi for a 0.15mg dose for pediatric use will help to expand the market. As investors look forward to the marketing of the drug by commercialization partner Sandoz, a division of Novartis (NVS), there are many events to which Adamis investors should pay close attention over the next several months.
Marketing Plan for Symjepi
As investors know,